AQR Capital Management LLC Purchases 111,826 Shares of Xeris Biopharma Holdings, Inc. $XERS

Key Points

• AQR Capital Management has increased its stake in Xeris Biopharma by 13.4%, owning approximately 0.61% of the company, which is valued at about $5.20 million.
• Xeris Biopharma's stock has experienced a drop of 2.5%, currently priced at $7.49, with a market cap of $1.21 billion.
• Despite recent insider sales, analysts maintain a Moderate Buy rating on Xeris Biopharma, with a consensus price target of $7.08.

AQR Capital Management LLC grew its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 13.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 946,766 shares of the company's stock after purchasing an additional 111,826 shares during the period. AQR Capital Management LLC owned approximately 0.61% of Xeris Biopharma worth $5,198,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Xeris Biopharma by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock valued at $44,522,000 after purchasing an additional 210,581 shares in the last quarter. Nuveen LLC purchased a new position in shares of Xeris Biopharma during the 1st quarter valued at $12,240,000. Millennium Management LLC grew its position in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after purchasing an additional 502,853 shares in the last quarter. Nuveen Asset Management LLC grew its position in shares of Xeris Biopharma by 13.6% during the 4th quarter. Nuveen Asset Management LLC now owns 1,903,442 shares of the company's stock valued at $6,453,000 after purchasing an additional 228,380 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its position in shares of Xeris Biopharma by 137.6% during the 1st quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock valued at $7,749,000 after purchasing an additional 817,525 shares in the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jeffrey W. Sherman sold 42,232 shares of the company's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the transaction, the director directly owned 219,188 shares of the company's stock, valued at approximately $1,735,968.96. This represents a 16.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Marla Persky sold 15,500 shares of the company's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the transaction, the director directly owned 142,000 shares of the company's stock, valued at approximately $1,096,240. This trade represents a 9.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 207,732 shares of company stock valued at $1,550,437. 6.47% of the stock is currently owned by insiders.

Xeris Biopharma Stock Up 8.2%

Shares of NASDAQ XERS traded up $0.63 during mid-day trading on Thursday, reaching $8.30. 3,971,149 shares of the company were exchanged, compared to its average volume of 1,728,867. The stock has a market capitalization of $1.34 billion, a PE ratio of -39.52 and a beta of 0.13. The company's 50 day moving average price is $6.70 and its 200 day moving average price is $5.38. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.69 and a 52 week high of $8.34.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. On average, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on XERS shares. HC Wainwright started coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target for the company. Wall Street Zen downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Finally, Leerink Partners lifted their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $7.08.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.